Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods

被引:19
作者
Al-Ogaidi, Israa [1 ,2 ]
Aguilar, Zoraida P. [2 ]
Suri, Savan [3 ]
Gou, Honglei [3 ]
Wu, Nianqiang [3 ]
机构
[1] Univ Baghdad, Coll Sci, Dept Biotechnol, Baghdad, Iraq
[2] Ocean Nanotech LLC, Springdale, AR USA
[3] W Virginia Univ, Dept Mech & Aerosp Engn, Morgantown, WV 26506 USA
关键词
D O I
10.1039/c3an00668a
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
An enzyme-linked immunoassay based on dual signal transduction mechanisms has been developed for detection of ovarian cancer biomarker CA125. The immunoassay uses a nanoelectrode array (NEA) chip and absorbance methods for the dual detection. The NEA is used to confirm the optical detection of CA125 that is carried out in a high-binding 96-well plate. An alkaline phosphatase (AP) enzyme was used to label the detection antibody to allow for both the optical and electrochemical detection of CA125. Two kinds of substrates were catalyzed by the AP enzyme. para-Nitrophenylphosphate (PNPP) produces chromogenic para-nitrophenol (PNP), which can be optically detected at 405 nm. para-Aminophenylphosphate (PAPP) produces electroactive para-aminophenol (PAP), which can be detected amperometrically between -0.1 and 0.3 V. The linear ranges have been determined to be 5-1000 U mL(-1) and 5-1000 U mL(-1) for the optical and electrochemical immunoassays, respectively. The limit of detection of the optical immunoassay is 1.3 U mL(-1) and 40 U mL(-1) for the optical and electrochemical methods, respectively.
引用
收藏
页码:5647 / 5653
页数:7
相关论文
共 27 条
  • [1] [Anonymous], 2003, EP OV CANC GUID NETW
  • [2] REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA
    BAST, RC
    FEENEY, M
    LAZARUS, H
    NADLER, LM
    COLVIN, RB
    KNAPP, RC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) : 1331 - 1337
  • [3] Bjerrum O.J., 1988, CRC Handbook of Immunoblotting of Proteins: Technical Description, V1
  • [4] Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Colombo, N.
    Peiretti, M.
    Parma, G.
    Lapresa, M.
    Mancari, R.
    Carinelli, S.
    Sessa, C.
    Castiglione, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : v23 - v30
  • [5] Cvetkovic Dusica, 2003, Reprod Biol Endocrinol, V1, P68
  • [6] Protein Detection Using Arrayed Microsensor Chips: Tuning Sensor Footprint to Achieve Ultrasensitive Readout of CA-125 in Serum and Whole Blood
    Das, Jagotamoy
    Kelley, Shana O.
    [J]. ANALYTICAL CHEMISTRY, 2011, 83 (04) : 1167 - 1172
  • [7] Emer and Katsumi, 2010, ELISA A Z INTRO PRAC
  • [8] Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis
    Emmanuel, Catherine
    Gava, Natalie
    Kennedy, Catherine
    Balleine, Rosemary L.
    Sharma, Raghwa
    Wain, Gerard
    Brand, Alison
    Hogg, Russell
    Etemadmoghadam, Dariush
    George, Joshy
    Birrer, Michael J.
    Clarke, Christine L.
    Chenevix-Trench, Georgia
    Bowtell, David D. L.
    Harnett, Paul R.
    deFazio, Anna
    [J]. PLOS ONE, 2011, 6 (03):
  • [9] Fehm T, 2005, ANTICANCER RES, V25, P1551
  • [10] Point of Care Diagnostics: Status and Future
    Gubala, Vladimir
    Harris, Leanne F.
    Ricco, Antonio J.
    Tan, Ming X.
    Williams, David E.
    [J]. ANALYTICAL CHEMISTRY, 2012, 84 (02) : 487 - 515